Boosting Fibroblast Growth Factor 13 in Brain Astrocytes Reduces Whole-Body Aging in Mice

Recent findings published in the scientific journal Aging Cell have cast new light on the systemic mechanisms of aging, pointing to a surprising command center located deep within the brain. Researchers have demonstrated that increasing the expression of fibroblast growth factor 13 (FGF13) specifically within astrocytes—a specialized type of star-shaped glial cell in the central nervous system—can significantly mitigate the physiological hallmarks of aging throughout the entire body of mice. This discovery bridges neurobiology and geroscience, suggesting that the brain does not merely succumb to chronological decay passively; rather, it may actively orchestrate systemic decline, and conversely, hold the key to systemic rejuvenation.

The study opens a fresh chapter in the exploration of the fibroblast growth factor (FGF) superfamily. Long recognized for their structural similarities and vital roles in embryonic development, wound healing, and metabolic regulation, FGF molecules have frequently surfaced in longevity research. Well-known family members, such as FGF21, have been extensively investigated for their capacity to regulate metabolic processes and extend lifespan. However, FGF13 has historically occupied a different category. Unlike its secreted counterparts that bind to classic cell-surface FGF receptors to trigger intercellular cascades, FGF13 is a non-secreted, intracellular protein whose functions operate independently of canonical receptor pathways. Prior studies had hinted at complex, context-dependent roles for FGF13, noting its neuroprotective benefits in experimental models of Parkinson’s disease alongside pathological implications in endothelial tissues during diabetes. Its direct involvement in mammalian aging, however, remained largely uncharted territory until now.

To unravel the trajectory of FGF13 over time, the research team initiated their investigation by analyzing public transcriptomic datasets encompassing both murine models and non-human primates, specifically macaques. The computational and histological data revealed a consistent age-related downregulation of FGF13 within the brain. While neuronal expression remained relatively stable, glial populations—including oligodendrocytes, microglia, and particularly astrocytes—exhibited a marked reduction in FGF13 levels as they aged. Interestingly, spatial dynamics within the murine brain varied; while FGF13 expression declined steadily within the hippocampus throughout the lifespan, it displayed an initial transient increase in the cerebral cortex at six months of age before commencing its eventual decline. Macaque datasets mirrored these patterns, demonstrating a robust concentration of FGF13 and an age-associated loss within astrocytic networks.

Recognizing this glial deficit, the investigators sought to determine whether the loss of FGF13 was merely a correlate of aging or an active driver of it. Using genetic knockout techniques, they selectively ablated FGF13 expression in the astrocytes of aging mice. The phenotypic consequences were pronounced and wide-ranging. Genetically modified mice exhibited accelerated cognitive decline, performing significantly worse on spatial learning and memory assessments such as the Morris water maze test when compared to age-matched control subjects.

Beyond cognitive impairment, the physiological degradation extended far beyond the blood-brain barrier. Despite the genetic intervention being strictly localized to astrocytes in the brain, the knockout mice developed widespread cellular senescence across peripheral organs, including the heart, skin, liver, spleen, and kidneys. Blood plasma analysis revealed elevated concentrations of circulating pro-inflammatory cytokines, painting a picture of systemic inflammation—often referred to in geroscience as "inflammaging." Based on these observations, the researchers concluded that the aging brain does not merely experience isolated degeneration; instead, it actively amplifies and transmits systemic aging signals via the circulatory system, accelerating the physical decline of peripheral tissues.

Seeking to test the reversibility of this phenomenon, the research team conducted a complementary intervention, utilizing viral vectors and genetic tools to overexpress FGF13 specifically within the astrocytes of older mice. The results offered a stark contrast to the knockout trials. In behavioral evaluations, treated older subjects demonstrated cognitive performance nearly indistinguishable from young, healthy mice, vastly outperforming their untreated counterparts. Additional spatial reasoning evaluations, such as the elevated plus maze and open field tests, confirmed robust improvements in exploratory behavior and anxiety-like profiles, though not fully reaching baseline youthful parameters.

The rejuvenation observed in the brain translated systemically. Despite the intervention remaining cell-type specific to cerebral astrocytes, analyses of peripheral tissues in the treated mice revealed a marked reduction in systemic inflammation. Circulating levels of key inflammatory cytokines, most notably interferon-gamma (IFN-γ) and interleukin-6 (IL-6), dropped substantially. Furthermore, tissues harvested from the skin, liver, spleen, and kidneys of the FGF13-overexpressing mice showed significantly diminished markers of cellular senescence, alongside a mitigation of age-related weight gain. While cardiac tissue did not exhibit statistically significant reductions in senescence markers, the breadth of the systemic response underscored a profound communication axis running from central glial cells to peripheral organs.

At the cellular and molecular level, the investigators sought to map the biochemical cascades responsible for these protective phenotypes. Through detailed in vitro assays and co-culture experiments, they discovered that FGF13 deficiency in astrocytes wreaks havoc on neighboring cellular networks. Astrocytes lacking FGF13 exhibited dramatic elevations in complement protein C3—a well-established biochemical marker of neurodegeneration—as well as connexin-43 (Cx43), an indicator of neuronal injury. When these deficient astrocytes were co-cultured with healthy neurons, synaptic integrity was visibly compromised. When co-cultured with microglia, the deficient astrocytes triggered the release of neurotoxic inflammatory factors. Conversely, overexpressing FGF13 reversed these pathological markers, restoring neuronal synaptic proteins, dampening microglial cytokine production, and clearing out degeneration-associated proteins.

To decode the precise intracellular mechanisms governing these protective shifts, the researchers performed comprehensive RNA sequencing on FGF13-overexpressing astrocytes. The transcriptomic profiling identified differential regulation of 820 genes—625 upregulated and 195 downregulated—affecting complex cellular pathways ranging from lysosomal transport and metabolic regulation to localized inflammatory signaling.

Crucially, biochemical pull-down assays revealed a direct physical interaction between FGF13 and Phafin2, an intracellular protein intimately linked to autophagy, the cellular recycling and housekeeping process that degrades damaged organelles and misfolded proteins. Like FGF13, Phafin2 expression declines naturally with age in mice. When researchers boosted FGF13 levels, Phafin2 activity was correspondingly enhanced. Brain tissue histology confirmed that FGF13 overexpression stimulated autophagy, evidenced by a significant accumulation of autophagosomes, autolysosomes, and canonical autophagy markers such as P62 and LC3. These findings suggest that FGF13 acts as an upstream regulator of cellular maintenance, ensuring that astrocytes retain their metabolic fitness and waste-clearance capabilities well into advanced age.

The implications of this study extend well beyond murine models, offering a compelling framework for future therapeutic exploration in human longevity and age-related pathologies. For decades, therapeutic strategies targeting neurodegenerative and systemic aging have focused primarily on peripheral interventions or direct neuronal targeting. This research highlights the critical, often underappreciated role of glial cells—specifically astrocytes—as central nodes in the regulation of whole-body aging. By demonstrating that molecular reinforcement within a localized population of brain cells can suppress systemic inflammation, clear peripheral senescence, and preserve cognitive function, the findings point toward a unified theory of mammalian aging coordinated by the central nervous system.

Nevertheless, experts emphasize that translating these preclinical insights into human clinical applications remains a distant horizon. The current study relied on genetic and viral vector manipulations in laboratory mice, methodologies that cannot be directly transposed to human patients without extensive safety, efficacy, and delivery optimization. Developing pharmacological agents or gene-delivery platforms capable of precisely modulating intracellular FGF13 within human astrocytes without causing off-target oncogenic or metabolic disruptions will require years of rigorous translational research.

As the scientific community continues to map the intricate signaling pathways that connect brain health to systemic longevity, this study serves as a foundational step. It establishes that the aging trajectory of the human body may be far more centralized than previously understood, offering hope that future interventions targeting cerebral glial maintenance could one day delay, or even reverse, the multifaceted decline associated with growing older.